Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
To estimate the survival outcomes of pembrolizumab relative to BRAF inhibitors vemurafenib and dabrafenib for the first line (1L) treatment of advanced-stage melanoma in BRAF mutation positive patients who are naïve to treatment with ipilimumab.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
